A review of phosphodiesterase type 5 inhibitors

Natalie Schellack, A. Agoro

Research output: Contribution to journalLiterature reviewpeer-review

8 Citations (Scopus)


Currently, three phosphodiesterase type 5 (PDE5) inhibitors are available for clinical use in South Africa; sildenafil, vardenafil and tadalafil. The PDE inhibitors are used in males to treat erectile dysfunction. However, sildenafil is also registered for use in the treatment of pulmonary hypertension. Newer studies are investigating the use of these drugs for other conditions, including hypertension, ischaemia or reperfusion injury, myocardial infarction, cardiac hypertrophy, heart failure and other peripheral circulatory conditions, e.g. Raynaud's disease. The article provides a broad overview of the mechanism of action, indications, pharmacokinetics and side-effects of these agents. © Medpharm.
Original languageEnglish
Pages (from-to)96-101
Number of pages6
JournalSouth African Family Practice
Publication statusPublished - 1 Jan 2014
Externally publishedYes


Dive into the research topics of 'A review of phosphodiesterase type 5 inhibitors'. Together they form a unique fingerprint.

Cite this